Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
Top Cited Papers
- 1 December 2000
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 356 (9245), 1876-1881
- https://doi.org/10.1016/s0140-6736(00)03258-x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast CancerNew England Journal of Medicine, 1999
- Population-based study of risk of breast cancer in carriers of BRCA2 mutationThe Lancet, 1998
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- BRCA-associated breast cancer in young women.Journal of Clinical Oncology, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesAmerican Journal of Human Genetics, 1998
- Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1The Lancet, 1998
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to CancerJAMA, 1997
- Rapid detection of BRCA1 mutations by the protein truncation testNature Genetics, 1995